NASDAQ:RENB Renovaro (RENB) Stock Price, News & Analysis → Hurry! Buy this stock before the Robinhood traders do! (From Traders Agency) (Ad) Free RENB Stock Alerts $1.29 -0.04 (-3.01%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share Today's Range$1.28▼$1.4350-Day Range$0.92▼$3.0052-Week Range$0.39▼$5.25Volume157,700 shsAverage Volume344,616 shsMarket Capitalization$190.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Renovaro alerts: Email Address Ad HedgeyeNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analysis meets hedge fund-level market foresight!TRY "INVESTING IDEAS" TODAY About Renovaro Stock (NASDAQ:RENB)Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.Read More RENB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RENB Stock News HeadlinesMay 24, 2024 | globenewswire.comRenovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer ImmunotherapyMay 24, 2024 | tmcnet.comBiotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032May 16, 2024 | finance.yahoo.comRenovaro Inc. (RENB)May 16, 2024 | investorplace.comRENB Stock Earnings: Renovaro Biosciences Reported Results for Q3 2024May 15, 2024 | washingtonpost.comRenovaro: Fiscal Q3 Earnings SnapshotApril 30, 2024 | globenewswire.comTransforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on FragmentomicsApril 24, 2024 | globenewswire.comRenovaroCube to Acquire 100% Ownership of Cyclomics, Reinforcing Cutting-Edge Cancer Diagnostics PartnershipApril 20, 2024 | uk.investing.comRenovaro appoints distinguished professor as new Chair of Scientific BoardApril 18, 2024 | finance.yahoo.comRenovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board, A Move That Heralds a New Era of Innovation and Progress in its Mission to Reshape Cancer Screening, Diagnosis, and Patient CareMarch 12, 2024 | markets.businessinsider.comONGOING INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RenovaroMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBMarch 10, 2024 | markets.businessinsider.comINVESTOR REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RenovaroMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 28, 2024 | stockhouse.comRenovaro Shareholder NoticeFebruary 26, 2024 | stockhouse.comRenovaro Shareholder AlertFebruary 25, 2024 | prnewswire.comROSEN, LEADING INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENBFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 23, 2024 | finance.yahoo.comRENB Apr 2024 2.500 callFebruary 22, 2024 | investorplace.comRed Flag Alert: 3 Stocks That Hindenburg Research Is Shorting NowFebruary 18, 2024 | markets.businessinsider.comRenovaro Ongoing Investor AlertFebruary 17, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 16, 2024 | prnewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Renovaro Biosciences Inc. Investors to Inquire About Securities Class Action Investigation - RENBFebruary 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Renovaro Biosciences Inc. - RENBFebruary 15, 2024 | globenewswire.comCutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplaceFebruary 14, 2024 | sg.finance.yahoo.comHit With Short Seller Report, Renovaro Biosciences Comments On Hindenburg's Opinion PieceSee More Headlines Receive RENB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renovaro and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/10/2024Fiscal Year End6/30/2024Next Earnings (Estimated)10/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RENB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone305-918-1980FaxN/AEmployees12Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,680,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-59.59% Return on Assets-47.14% Debt Debt-to-Equity RatioN/A Current Ratio0.06 Quick Ratio0.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.80 per share Price / Book1.61Miscellaneous Outstanding Shares147,510,000Free Float115,467,000Market Cap$190.29 million OptionableOptionable Beta0.44 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesHon. Mark R. Dybul M.D. (Age 60)CEO, Director & Member of HBV Scientific Advisory Board Comp: $764.58kDr. Francois Binette M.Sc. (Age 60)Ph.D., COO and Executive VP for Research & Development Comp: $504.38kDr. Serhat GümrükcüCo-Founder & InventorMr. Simon Tarsh (Age 62)Interim Chief Financial Officer Mr. Greg Duczynski Ph.D.Senior Vice President for Clinical OperationsKey CompetitorsAurinia PharmaceuticalsNASDAQ:AUPHZentalis PharmaceuticalsNASDAQ:ZNTLTango TherapeuticsNASDAQ:TNGXOlema PharmaceuticalsNASDAQ:OLMAEvolusNASDAQ:EOLSView All CompetitorsInstitutional OwnershipTidal Investments LLCBought 36,972 shares on 5/17/2024Ownership: 0.026%Vanguard Group Inc.Bought 3,526,565 shares on 5/10/2024Ownership: 2.726%SG Americas Securities LLCBought 17,263 shares on 5/7/2024Ownership: 0.012%View All Institutional Transactions RENB Stock Analysis - Frequently Asked Questions How have RENB shares performed in 2024? Renovaro's stock was trading at $3.17 at the beginning of 2024. Since then, RENB stock has decreased by 59.3% and is now trading at $1.29. View the best growth stocks for 2024 here. When is Renovaro's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, October 7th 2024. View our RENB earnings forecast. How were Renovaro's earnings last quarter? Renovaro Inc. (NASDAQ:RENB) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.08) earnings per share (EPS) for the quarter. What ETF holds Renovaro's stock? Amplify Treatments, Testing and Advancements ETF holds 33,976 shares of RENB stock, representing 0.45% of its portfolio. Who are Renovaro's major shareholders? Renovaro's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.73%), Tidal Investments LLC (0.03%) and SG Americas Securities LLC (0.01%). How do I buy shares of Renovaro? Shares of RENB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RENB) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renovaro Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Renovaro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.